Literature DB >> 16931204

Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex.

Ralf Wienecke1, Ingrid Fackler, Ulrich Linsenmaier, Karin Mayer, Thomas Licht, Matthias Kretzler.   

Abstract

A 19-year old patient with tuberous sclerosis presented with a renal angiomyolipoma. Because animal trials of tuberous sclerosis showed an effect of rapamycin on renal tumors, our patient was administered rapamycin for 6 months. During this time, the renal angiomyolipoma shrank significantly, regrew during an 8-month period, and decreased in size again after readministration of rapamycin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16931204     DOI： 10.1053/j.ajkd.2006.05.018

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  31 in total

1.  Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration.

Authors:  J Stuart Nelson; Wangcun Jia; Thuy L Phung; Martin C Mihm
Journal:  Lasers Surg Med       Date:  2011-11-29       Impact factor: 4.025

Review 2.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

3.  [Tuberous sclerosis: diagnostic criteria and new treatment approaches].

Authors:  S Grieb; R Kruse; D Bruch-Gerharz; J Reifenberger
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

4.  Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis.

Authors:  Michael Staehler; Matthias Sauter; Andreas Helck; Ulrich Linsenmaier; Lutz Weber; Karin Mayer; Michael Fischereder
Journal:  Int Urol Nephrol       Date:  2012-09-28       Impact factor: 2.370

5.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

6.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

7.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

8.  Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.

Authors:  Sangyeul Han; Carolyn Polizzano; Gunnlaugur P Nielsen; Francis J Hornicek; Andrew E Rosenberg; Vijaya Ramesh
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.

Authors:  Wenbin Tan; Wangcun Jia; Victor Sun; Martin C Mihm; J Stuart Nelson
Journal:  Lasers Surg Med       Date:  2012-12-04       Impact factor: 4.025

Review 10.  Neurofibromatosis type 1.

Authors:  Kevin P Boyd; Bruce R Korf; Amy Theos
Journal:  J Am Acad Dermatol       Date:  2009-07       Impact factor: 11.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.